Table 3.
Response and number of [177Lu]Lu-DOTA-ZOL treatment cycles administered according to the extent of disease
| Extent of skeletal metastases | Number of patients (%) | Response according to VAS assessment criteria (number of patients) | Number of cycles administered | Response according to global pain assessment criteria (number of patients) | Number of cycles administered |
|---|---|---|---|---|---|
| < 6 | 2 (5%) | CR-1 | 2C | PR-2 | 1st patient-1C |
| PR-1 | 1C | 2nd patient-2C | |||
| 6–20 | 17 (42.5%) | CR-5 | 4 patients-2C, 1 patient-1C | CR-1 | 2C |
| PR-9 | 5 patients-2C, 4 patients-1C | PR-11 | 8 patients-2C, 3 patients-1C | ||
| MR-1 | 2C | MR-3 | 2 patients-1C, 1 patient-2C | ||
| NR-2 | Both patients-1C | NR-2 | Both patients-1C | ||
| > 20 | 7 (17.5%) | CR-2 | 2 patients, 2C | CR-1 | 2C |
| PR-4 | 3 patients-2C, 1 patient-1C | PR-4 | 3 patients-2C, 1 patient-1C | ||
| MR-0 | 0 | MR-1 | 2C | ||
| NR-1 | 1C | NR-1 | 1C | ||
| Superscan/diffuse | 14 (35%) | CR-3 | All patients-2C | CR-0 | – |
| PR-6 | 5 patients-2C, 1 patient-1C | PR-8 | 6 patients-2C, 2 patients-1C | ||
| MR-4 | 1 patient-2C, 3 patients-1C | MR-5 | 3 patients-2C, 2 patients-1C | ||
| NR-1 | 1 patient 1C | NR-1 | 1C |
VAS visual analogue score, CR complete response, PR partial response, MR minimal response, NR no response, C cycles